About Nathalie Riebel

Over 30 years in oncology clinical trials

I’m an independent, hands-on clinical operations leader who’s run every kind of oncology trial, from first-in-human dose escalation through global phase 3, including investigator-initiated and master protocols. Founders bring me in when they have a promising asset and need an operator to take it into the clinic

13+

years in Pharma

GW • GSK • Eli Lilly

CRA at G and GW, led clinical operations teams at GSK, and led the oncology franchise inspection readiness program/team at Eli Lilly.

15+

years in CRO Leadership

IQVIA • ICON

Led project management, portfolio and program delivery, and full trial teams as a Director across mid-size and small Oncology Biotechs.

7+

years in Biotech Leadership

ImClone • Delcath • PDS Biotech

Built clinical operations from the ground up: the departments, standards, systems, and teams early-stage biotechs don't have yet.

Three decades across pharma, CRO, and biotech. Here's what it does for you.

Clinical trial consultant Nathalie Riebel of Oncospire presenting CRO oversight strategy to biotech leadership team

If you're a founder with a promising molecule in preclinical and no in-house clinical operations, this is where I come in. I design and operationalize your first-in-human trial, then run it from IND filing through first patient dosed, topline results, and into your next phase of development.

  • Operational protocol design

  • CRO selection and oversight

  • Phase 1 and phase 2 trial setup and execution

  • Fit-for-purpose vendor oversight, right-sized to your trial, not a bloated system

  • Study conduct through database lock and topline readout

  • Inspection readiness and next-phase planning

I'm not an MD guessing at operations. I'm the operator, from IND filing to topline results and beyond.

Experience across 18+ Indications

Tumor Types

Treatment Modalities

Publications

Built to withstand the inspection before it happens.

When Eli Lilly acquired ImClone Systems, I was chosen to lead inspection readiness for Lilly's oncology franchise, a role created specifically for me. Over 4 years, I built the program from the ground up. I assembled a joint team of ImClone and Lilly quality assurance professionals, shepherded ImClone's drugs through global regulatory inspections, and trained the Lilly team leaders who inherited the programs. I led the backroom during inspections, crafted responses to regulatory agencies, and coached site staff on how to respond to inspectors.

27 FDA inspections. No OAI and 1 company VAI 

Inspection readiness isn't something you scramble for when the FDA calls. It's built into how a trial runs from day one. That's how I run yours, so when scrutiny comes, your trial is already prepared for it.

Clinical trial consultant Nathalie Riebel of Oncospire Consultants specializing in CRO selection and oversight systems

25+

people on the largest team led

$70M

portfolio budget managed

17+

trials from setup to execution

You have a molecule in preclinical. Let's get it to first patient dose.

Working alongside your team, I design and operationalize your first-in-human study so it meets its milestones, withstands scrutiny, and stays on timeline.